{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:44:18Z","timestamp":1790703858484,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic","award":["VEGA 1\/0016\/20"],"award-info":[{"award-number":["VEGA 1\/0016\/20"]}]},{"name":"The Slovak Research and Development Agency","award":["APVV-20-0242, APPV-15-0607"],"award-info":[{"award-number":["APVV-20-0242, APPV-15-0607"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11010-022-04621-y","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:05:51Z","timestamp":1670259951000},"page":"1661-1667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection"],"prefix":"10.1007","volume":"478","author":[{"given":"Andrey","family":"Svec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-043X","authenticated-orcid":false,"given":"Adriana","family":"Adameova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"4621_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","volume":"328","author":"JE Blais","year":"2021","unstructured":"Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R, Lau WCY, Man KKC, Siu CW, Tan KCB, Wong ICK, Wei L, Chan EW (2021) Trends in lipid-modifying agent use in 83 countries. Atherosclerosis 328:44\u201351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.016","journal-title":"Atherosclerosis"},{"key":"4621_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423. https:\/\/doi.org\/10.1136\/bmj.326.7404.1423","journal-title":"BMJ"},{"key":"4621_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s0002-9149(03)00530-7","volume":"92","author":"PH Jones","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, Group SS (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 92:152\u201360. https:\/\/doi.org\/10.1016\/s0002-9149(03)00530-7","journal-title":"Am J Cardiol"},{"key":"4621_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","volume":"105","author":"SJ Nicholls","year":"2010","unstructured":"Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ (2010) Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105:69\u201376. https:\/\/doi.org\/10.1016\/j.amjcard.2009.08.651","journal-title":"Am J Cardiol"},{"key":"4621_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/sqb.2002.67.491","volume":"67","author":"JD Horton","year":"2002","unstructured":"Horton JD, Goldstein JL, Brown MS (2002) SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol 67:491\u2013498. https:\/\/doi.org\/10.1101\/sqb.2002.67.491","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"4621_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/s0092-8674(00)80213-5","volume":"89","author":"MS Brown","year":"1997","unstructured":"Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331\u2013340. https:\/\/doi.org\/10.1016\/s0092-8674(00)80213-5","journal-title":"Cell"},{"key":"4621_CR7","doi-asserted-by":"publisher","first-page":"36B","DOI":"10.1016\/s0002-9149(98)00036-8","volume":"81","author":"GL Vega","year":"1998","unstructured":"Vega GL, Grundy SM (1998) Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 81:36B-42B. https:\/\/doi.org\/10.1016\/s0002-9149(98)00036-8","journal-title":"Am J Cardiol"},{"key":"4621_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/s0002-9149(96)00441-9","volume":"78","author":"WC Roberts","year":"1996","unstructured":"Roberts WC (1996) The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 78:377\u2013378. https:\/\/doi.org\/10.1016\/s0002-9149(96)00441-9","journal-title":"Am J Cardiol"},{"key":"4621_CR9","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/pl00012505","volume":"59","author":"NR Veillard","year":"2002","unstructured":"Veillard NR, Mach F (2002) Statins: the new aspirin? Cell Mol Life Sci 59:1771\u20131786. https:\/\/doi.org\/10.1007\/pl00012505","journal-title":"Cell Mol Life Sci"},{"key":"4621_CR10","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388:2532\u20132561. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5","journal-title":"Lancet"},{"key":"4621_CR11","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670\u20131681. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5","journal-title":"Lancet"},{"key":"4621_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/01.cir.103.1.113","volume":"103","author":"O Feron","year":"2001","unstructured":"Feron O, Dessy C, Desager JP, Balligand JL (2001) Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103:113\u2013118. https:\/\/doi.org\/10.1161\/01.cir.103.1.113","journal-title":"Circulation"},{"key":"4621_CR13","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1161\/01.CIR.0000065601.83526.3E","volume":"107","author":"M Pelat","year":"2003","unstructured":"Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL (2003) Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-\/- mice in vivo. Circulation 107:2480\u20132486. https:\/\/doi.org\/10.1161\/01.CIR.0000065601.83526.3E","journal-title":"Circulation"},{"key":"4621_CR14","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/01.hyp.37.6.1450","volume":"37","author":"S Wassmann","year":"2001","unstructured":"Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, Nickenig G (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37:1450\u20131457. https:\/\/doi.org\/10.1161\/01.hyp.37.6.1450","journal-title":"Hypertension"},{"key":"4621_CR15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1161\/hq0202.104081","volume":"22","author":"S Wassmann","year":"2002","unstructured":"Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300\u2013305. https:\/\/doi.org\/10.1161\/hq0202.104081","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4621_CR16","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1111\/bph.14781","volume":"176","author":"CC Hsieh","year":"2019","unstructured":"Hsieh CC, Li CY, Hsu CH, Chen HL, Chen YH, Liu YP, Liu YR, Kuo HF, Liu PL (2019) Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure. Br J Pharmacol 176:3791\u20133804. https:\/\/doi.org\/10.1111\/bph.14781","journal-title":"Br J Pharmacol"},{"issue":"488\u201396","key":"4621_CR17","doi-asserted-by":"publisher","first-page":"W174","DOI":"10.7326\/0003-4819-152-8-201004200-00005","volume":"152","author":"RJ Glynn","year":"2010","unstructured":"Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM (2010) Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 152(488\u201396):W174. https:\/\/doi.org\/10.7326\/0003-4819-152-8-201004200-00005","journal-title":"Ann Intern Med"},{"key":"4621_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1291\/hypres.23.353","volume":"23","author":"K Egashira","year":"2000","unstructured":"Egashira K, Ni W, Inoue S, Kataoka C, Kitamoto S, Koyanagi M, Takeshita A (2000) Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res 23:353\u2013358. https:\/\/doi.org\/10.1291\/hypres.23.353","journal-title":"Hypertens Res"},{"key":"4621_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/01.atv.20.2.556","volume":"20","author":"T Bourcier","year":"2000","unstructured":"Bourcier T, Libby P (2000) HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20:556\u2013562. https:\/\/doi.org\/10.1161\/01.atv.20.2.556","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4621_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/s0002-9149(99)00745-6","volume":"85","author":"CA Dujovne","year":"2000","unstructured":"Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM (2000) Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 85:350\u2013353. https:\/\/doi.org\/10.1016\/s0002-9149(99)00745-6","journal-title":"Am J Cardiol"},{"key":"4621_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","volume":"7","author":"BG Schultz","year":"2018","unstructured":"Schultz BG, Patten DK, Berlau DJ (2018) The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener 7:5. https:\/\/doi.org\/10.1186\/s40035-018-0110-3","journal-title":"Transl Neurodegener"},{"key":"4621_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00415-009-5271-7","volume":"257","author":"S Trompet","year":"2010","unstructured":"Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Westendorp RG (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257:85\u201390. https:\/\/doi.org\/10.1007\/s00415-009-5271-7","journal-title":"J Neurol"},{"key":"4621_CR23","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/s0140-6736(02)11600-x","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PsgPSoPitEa R (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623\u20131630. https:\/\/doi.org\/10.1016\/s0140-6736(02)11600-x","journal-title":"Lancet"},{"key":"4621_CR24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1592\/phco.29.7.800","volume":"29","author":"MA Evans","year":"2009","unstructured":"Evans MA, Golomb BA (2009) Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 29:800\u2013811. https:\/\/doi.org\/10.1592\/phco.29.7.800","journal-title":"Pharmacotherapy"},{"key":"4621_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","volume":"29","author":"E Olmastroni","year":"2022","unstructured":"Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, Zambon A, Catapano AL, Casula M (2022) Statin use and risk of dementia or alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol 29:804\u2013814. https:\/\/doi.org\/10.1093\/eurjpc\/zwab208","journal-title":"Eur J Prev Cardiol"},{"key":"4621_CR26","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1535-7163.MCT-06-0745","volume":"6","author":"WW Wong","year":"2007","unstructured":"Wong WW, Clendening JW, Martirosyan A, Boutros PC, Bros C, Khosravi F, Jurisica I, Stewart AK, Bergsagel PL, Penn LZ (2007) Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 6:1886\u20131897. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0745","journal-title":"Mol Cancer Ther"},{"key":"4621_CR27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.59566\/IJBS.2009.5411","volume":"5","author":"ME Crescencio","year":"2009","unstructured":"Crescencio ME, Rodriguez E, Paez A, Masso FA, Montano LF, Lopez-Marure R (2009) Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells. Int J Biomed Sci 5:411\u2013420","journal-title":"Int J Biomed Sci"},{"issue":"Suppl 2","key":"4621_CR28","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.33549\/physiolres.932420","volume":"61","author":"T Rajtik","year":"2012","unstructured":"Rajtik T, Carnicka S, Szobi A, Mesarosova L, Matus M, Svec P, Ravingerova T, Adameova A (2012) Pleiotropic effects of simvastatin are associated with mitigation of apoptotic component of cell death upon lethal myocardial reperfusion-induced injury. Physiol Res 61(Suppl 2):S33-41","journal-title":"Physiol Res"},{"key":"4621_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.33549\/physiolres.931751","volume":"58","author":"A Adameova","year":"2009","unstructured":"Adameova A, Harcarova A, Matejikova J, Pancza D, Kuzelova M, Carnicka S, Svec P, Bartekova M, Styk J, Ravingerova T (2009) Simvastatin alleviates myocardial contractile dysfunction and lethal ischemic injury in rat heart independent of cholesterol-lowering effects. Physiol Res 58:449\u2013454","journal-title":"Physiol Res"},{"key":"4621_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11904-015-0273-9","volume":"12","author":"AR Eckard","year":"2015","unstructured":"Eckard AR, McComsey GA (2015) The role of statins in the setting of HIV infection. Curr HIV\/AIDS Rep 12:305\u2013312. https:\/\/doi.org\/10.1007\/s11904-015-0273-9","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4621_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40263-015-0239-x","volume":"29","author":"G Pihl-Jensen","year":"2015","unstructured":"Pihl-Jensen G, Tsakiri A, Frederiksen JL (2015) Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 29:277\u2013291. https:\/\/doi.org\/10.1007\/s40263-015-0239-x","journal-title":"CNS Drugs"},{"key":"4621_CR32","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1365-2125.2012.04403.x","volume":"75","author":"NL Zaharan","year":"2013","unstructured":"Zaharan NL, Williams D, Bennett K (2013) Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 75:1118\u20131124. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04403.x","journal-title":"Br J Clin Pharmacol"},{"key":"4621_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2610","volume":"346","author":"AA Carter","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ 346:f2610. https:\/\/doi.org\/10.1136\/bmj.f2610","journal-title":"BMJ"},{"key":"4621_CR34","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s11739-020-02504-y","volume":"15","author":"R Rossi","year":"2020","unstructured":"Rossi R, Talarico M, Coppi F, Boriani G (2020) Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Intern Emerg Med 15:1573\u20131576. https:\/\/doi.org\/10.1007\/s11739-020-02504-y","journal-title":"Intern Emerg Med"},{"key":"4621_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9090759","author":"SL Song","year":"2020","unstructured":"Song SL, Hays SB, Panton CE, Mylona EK, Kalligeros M, Shehadeh F, Mylonakis E (2020) Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: a preliminary study. Pathogens. https:\/\/doi.org\/10.3390\/pathogens9090759","journal-title":"Pathogens"},{"issue":"176\u2013187","key":"4621_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.06.015","volume":"32","author":"XJ Zhang","year":"2020","unstructured":"Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, Song X, Lin L, Xia M, Zhou F, Zhou J, She ZG, Zhu L, Ma X, Xu Q, Ye P, Chen G, Liu L, Mao W, Yan Y, Xiao B, Lu Z, Peng G, Liu M, Yang J, Yang L, Zhang C, Lu H, Xia X, Wang D, Liao X, Wei X, Zhang BH, Zhang X, Yang J, Zhao GN, Zhang P, Liu PP, Loomba R, Ji YX, Xia J, Wang Y, Cai J, Guo J, Li H (2020) In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 32(176\u2013187):e4. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.015","journal-title":"Cell Metab"},{"key":"4621_CR37","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1161\/CIRCULATIONAHA.105.552257","volume":"114","author":"AM Gotto Jr","year":"2006","unstructured":"Gotto AM Jr (2006) Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. Circulation 114:1310\u20131314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.552257","journal-title":"Circulation"},{"key":"4621_CR38","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection E and Treatment of High Blood Cholesterol in A","year":"2001","unstructured":"Expert Panel on Detection E and Treatment of High Blood Cholesterol in A (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486\u20132497. https:\/\/doi.org\/10.1001\/jama.285.19.2486","journal-title":"JAMA"},{"key":"4621_CR39","doi-asserted-by":"publisher","first-page":"35F","DOI":"10.1016\/j.amjcard.2004.07.053","volume":"94","author":"DB Nash","year":"2004","unstructured":"Nash DB, Nash SA (2004) Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy. Am J Cardiol 94:35F-39F. https:\/\/doi.org\/10.1016\/j.amjcard.2004.07.053","journal-title":"Am J Cardiol"},{"key":"4621_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s11096-012-9668-5","volume":"34","author":"V Paudyal","year":"2012","unstructured":"Paudyal V, Hansford D, Cunningham S, Stewart D (2012) Pharmacists\u2019 perceived integration into practice of over-the-counter simvastatin five years post reclassification. Int J Clin Pharm 34:733\u2013738. https:\/\/doi.org\/10.1007\/s11096-012-9668-5","journal-title":"Int J Clin Pharm"},{"key":"4621_CR41","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160\u20131164. https:\/\/doi.org\/10.1126\/science.1059344","journal-title":"Science"},{"key":"4621_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00003495-199142010-00005","volume":"42","author":"D McTavish","year":"1991","unstructured":"McTavish D, Sorkin EM (1991) Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42:65\u201389. https:\/\/doi.org\/10.2165\/00003495-199142010-00005","journal-title":"Drugs"},{"key":"4621_CR43","doi-asserted-by":"publisher","first-page":"28B","DOI":"10.1016\/s0002-9149(01)01454-0","volume":"87","author":"F McTaggart","year":"2001","unstructured":"McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M (2001) Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87:28B-32B. https:\/\/doi.org\/10.1016\/s0002-9149(01)01454-0","journal-title":"Am J Cardiol"},{"key":"4621_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s0163-7258(99)00045-5","volume":"84","author":"A Corsini","year":"1999","unstructured":"Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413\u2013428. https:\/\/doi.org\/10.1016\/s0163-7258(99)00045-5","journal-title":"Pharmacol Ther"},{"key":"4621_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117\u2013125. https:\/\/doi.org\/10.1111\/j.1472-8206.2004.00299.x","journal-title":"Fundam Clin Pharmacol"},{"key":"4621_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/0049825031000066259","volume":"33","author":"K Nezasa","year":"2003","unstructured":"Nezasa K, Higaki K, Takeuchi M, Nakano M, Koike M (2003) Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33:379\u2013388. https:\/\/doi.org\/10.1080\/0049825031000066259","journal-title":"Xenobiotica"},{"key":"4621_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/s0195-668x(02)00419-0","volume":"24","author":"PO Bonetti","year":"2003","unstructured":"Bonetti PO, Lerman LO, Napoli C, Lerman A (2003) Statin effects beyond lipid lowering\u2013are they clinically relevant? Eur Heart J 24:225\u2013248. https:\/\/doi.org\/10.1016\/s0195-668x(02)00419-0","journal-title":"Eur Heart J"},{"key":"4621_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89\u2013118. https:\/\/doi.org\/10.1146\/annurev.pharmtox.45.120403.095748","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4621_CR49","doi-asserted-by":"publisher","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","volume":"109","author":"J Davignon","year":"2004","unstructured":"Davignon J (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109:III39-43. https:\/\/doi.org\/10.1161\/01.CIR.0000131517.20177.5a","journal-title":"Circulation"},{"key":"4621_CR50","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.2174\/138161209789058048","volume":"15","author":"A Adameova","year":"2009","unstructured":"Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS (2009) Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Curr Pharm Des 15:3094\u20133107","journal-title":"Curr Pharm Des"},{"key":"4621_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.drudis.2016.09.001","volume":"22","author":"DM Muntean","year":"2017","unstructured":"Muntean DM, Thompson PD, Catapano AL, Stasiolek M, Fabis J, Muntner P, Serban MC, Banach M (2017) Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 22:85\u201396. https:\/\/doi.org\/10.1016\/j.drudis.2016.09.001","journal-title":"Drug Discov Today"},{"key":"4621_CR52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3138\/ptc.2012-65","volume":"66","author":"P Mendes","year":"2014","unstructured":"Mendes P, Robles PG, Mathur S (2014) Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can 66:124\u2013132. https:\/\/doi.org\/10.3138\/ptc.2012-65","journal-title":"Physiother Can"},{"key":"4621_CR53","doi-asserted-by":"publisher","first-page":"598","DOI":"10.7326\/0003-4819-132-7-200004040-00031","volume":"132","author":"ML Rodriguez","year":"2000","unstructured":"Rodriguez ML, Mora C, Navarro JF (2000) Cerivastatin-induced rhabdomyolysis. Ann Intern Med 132:598. https:\/\/doi.org\/10.7326\/0003-4819-132-7-200004040-00031","journal-title":"Ann Intern Med"},{"key":"4621_CR54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/ndt\/15.5.740","volume":"15","author":"E Plotkin","year":"2000","unstructured":"Plotkin E, Bernheim J, Ben-Chetrit S, Mor A, Korzets Z (2000) Influenza vaccine\u2013a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol Dial Transplant 15:740\u2013741. https:\/\/doi.org\/10.1093\/ndt\/15.5.740","journal-title":"Nephrol Dial Transplant"},{"key":"4621_CR55","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/s0002-9149(99)00034-x","volume":"83","author":"GW Pogson","year":"1999","unstructured":"Pogson GW, Kindred LH, Carper BG (1999) Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 83:1146. https:\/\/doi.org\/10.1016\/s0002-9149(99)00034-x","journal-title":"Am J Cardiol"},{"key":"4621_CR56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0002-9343(00)00514-3","volume":"109","author":"G Alexandridis","year":"2000","unstructured":"Alexandridis G, Pappas GA, Elisaf MS (2000) Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 109:261\u2013262. https:\/\/doi.org\/10.1016\/s0002-9343(00)00514-3","journal-title":"Am J Med"},{"key":"4621_CR57","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/s0002-9343(01)00730-6","volume":"110","author":"G Gemici","year":"2001","unstructured":"Gemici G, Toprak A, Oktay A (2001) Rhabdomyolysis due to cerivastatin monotherapy. Am J Med 110:742. https:\/\/doi.org\/10.1016\/s0002-9343(01)00730-6","journal-title":"Am J Med"},{"key":"4621_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0167-5273(02)00581-8","volume":"91","author":"R Bakri","year":"2003","unstructured":"Bakri R, Wang J, Wierzbicki AS, Goldsmith D (2003) Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. Int J Cardiol 91:107\u2013109. https:\/\/doi.org\/10.1016\/s0167-5273(02)00581-8","journal-title":"Int J Cardiol"},{"key":"4621_CR59","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.ahj.2003.12.037","volume":"147","author":"SM Jamal","year":"2004","unstructured":"Jamal SM, Eisenberg MJ, Christopoulos S (2004) Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147:956\u2013965. https:\/\/doi.org\/10.1016\/j.ahj.2003.12.037","journal-title":"Am Heart J"},{"key":"4621_CR60","doi-asserted-by":"publisher","first-page":"CD012501","DOI":"10.1002\/14651858.CD012501.pub2","volume":"1","author":"SP Adams","year":"2020","unstructured":"Adams SP, Tiellet N, Alaeiilkhchi N, Wright JM (2020) Cerivastatin for lowering lipids. Cochrane Database Syst Rev 1:CD012501. https:\/\/doi.org\/10.1002\/14651858.CD012501.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4621_CR61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jamainternmed.2014.6388","volume":"175","author":"JM Pena","year":"2015","unstructured":"Pena JM, Aspberg S, MacFadyen J, Glynn RJ, Solomon DH, Ridker PM (2015) Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med 175:171\u2013177. https:\/\/doi.org\/10.1001\/jamainternmed.2014.6388","journal-title":"JAMA Intern Med"},{"key":"4621_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7326\/0003-4819-139-2-200307150-00009","volume":"139","author":"AZ LaCroix","year":"2003","unstructured":"LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD (2003) Statin use, clinical fracture, and bone density in postmenopausal women: results from the women\u2019s health initiative observational study. Ann Intern Med 139:97\u2013104. https:\/\/doi.org\/10.7326\/0003-4819-139-2-200307150-00009","journal-title":"Ann Intern Med"},{"key":"4621_CR63","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1001\/jama.285.14.1850","volume":"285","author":"TP van Staa","year":"2001","unstructured":"van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850\u20131855. https:\/\/doi.org\/10.1001\/jama.285.14.1850","journal-title":"JAMA"},{"key":"4621_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00198-016-3844-8","volume":"28","author":"T An","year":"2017","unstructured":"An T, Hao J, Sun S, Li R, Yang M, Cheng G, Zou M (2017) Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int 28:47\u201357. https:\/\/doi.org\/10.1007\/s00198-016-3844-8","journal-title":"Osteoporos Int"},{"key":"4621_CR65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CLEP.S145311","volume":"10","author":"TK Lin","year":"2018","unstructured":"Lin TK, Liou YS, Lin CH, Chou P, Jong GP (2018) High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clin Epidemiol 10:159\u2013165. https:\/\/doi.org\/10.2147\/CLEP.S145311","journal-title":"Clin Epidemiol"},{"key":"4621_CR66","doi-asserted-by":"publisher","first-page":"322","DOI":"10.12997\/jla.2021.10.3.322","volume":"10","author":"KJ Kim","year":"2021","unstructured":"Kim KJ, Choi J, Kim JY, Bae JH, Kim KJ, Kim HY, Yoo HJ, Seo JA, Kim NH, Choi KM, Baik SH, Kim SG, Kim NH (2021) Statin therapy and the risk of osteoporotic fractures in patients with metabolic syndrome: a nested case-control study. J Lipid Atheroscler 10:322\u2013333. https:\/\/doi.org\/10.12997\/jla.2021.10.3.322","journal-title":"J Lipid Atheroscler"},{"key":"4621_CR67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.55095\/achot2022\/015","volume":"89","author":"A Del Chiaro","year":"2022","unstructured":"Del Chiaro A, Marchetti S, Parchi PD, Caprili G, Ipponi E, Scaglione M (2022) Use of statins and hip fracture risk: a case-control study. Acta Chir Orthop Traumatol Cech 89:104\u2013107","journal-title":"Acta Chir Orthop Traumatol Cech"},{"key":"4621_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101152","volume":"16","author":"A Antonenko","year":"2022","unstructured":"Antonenko A, Leahy A, Babenko M, Lyons D (2022) Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis. Bone Rep 16:101152. https:\/\/doi.org\/10.1016\/j.bonr.2021.101152","journal-title":"Bone Rep"},{"key":"4621_CR69","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1210\/jcem.85.3.6476","volume":"85","author":"YS Chung","year":"2000","unstructured":"Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137\u20131142. https:\/\/doi.org\/10.1210\/jcem.85.3.6476","journal-title":"J Clin Endocrinol Metab"},{"key":"4621_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104514","volume":"155","author":"E Olmastroni","year":"2020","unstructured":"Olmastroni E, Boccalari MT, Tragni E, Rea F, Merlino L, Corrao G, Catapano AL, Casula M (2020) Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies. Pharmacol Res 155:104514. https:\/\/doi.org\/10.1016\/j.phrs.2019.104514","journal-title":"Pharmacol Res"},{"key":"4621_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201196","volume":"14","author":"HF Hope","year":"2019","unstructured":"Hope HF, Binkley GM, Fenton S, Kitas GD, Verstappen SMM, Symmons DPM (2019) Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE 14:e0201196. https:\/\/doi.org\/10.1371\/journal.pone.0201196","journal-title":"PLoS ONE"},{"key":"4621_CR72","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010376","volume":"8","author":"LD Colantonio","year":"2019","unstructured":"Colantonio LD, Rosenson RS, Deng L, Monda KL, Dai Y, Farkouh ME, Safford MM, Philip K, Mues KE, Muntner P (2019) Adherence to statin therapy among US adults between 2007 and 2014. J Am Heart Assoc 8:e010376. https:\/\/doi.org\/10.1161\/JAHA.118.010376","journal-title":"J Am Heart Assoc"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04621-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:57:33Z","timestamp":1744210653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04621-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4621"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04621-y","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review article and ethical approval is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}